The phenotypic and functional consequences of tumour necrosis factor receptor type 2 expression on CD4+FoxP3+ regulatory T cells

Immunology

Volumn 133, Issue 4, 2011, Pages 426-433

  Chen, Xin ^a   Oppenheim, Joost J ^b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CD4+FoxP3+ regulatory T cells; CD4+FoxP3 effector T cells; Immunological phenotype; Immunosuppression; Tumour necrosis factor receptor 2

Indexed keywords

CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR RECEPTOR 2;

CD4+ T LYMPHOCYTE; HUMAN; INFLAMMATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW;

ANIMALS; ANTIGENS, CD4; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; PHENOTYPE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; T-LYMPHOCYTES, REGULATORY;

EID: 79959902280     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2011.03460.x     Document Type: Review

References (53)

1. Gershon RK, Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 1970; 18:723-37.
2. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151-64.
3. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6:345-52.
4. + T regulatory cell-mediated suppression. Immunity 2009; 30:636-45.
5. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006; 212:28-50.
6. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 2001; 182:207-14.
7. Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 1995; 5:392-9.
8. Grell M, Douni E, Wajant H et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80kDa tumor necrosis factor receptor. Cell 1995; 83:793-802.
9. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002; 296:1634-5.
10. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001; 4:1116-22.
11. Kim EY, Priatel JJ, Teh SJ, Teh HS. TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo. J Immunol 2006; 176:1026-35.
12. Kim EY, Teh HS. TNF type 2 receptor (p75) lowers the threshold of T cell activation. J Immunol 2001; 167:6812-20.
13. Kim EY, Teh HS. Critical role of TNF receptor type-2 (p75) as a costimulator for IL-2 induction and T cell survival: a functional link to CD28. J Immunol 2004; 173:4500-9.
14. + regulatory T cells inhibits the induction of inflammatory mediators. J Immunol 2008; 180:2747-51.
15. + T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J Immunol 2008; 180:6467-71.
16. + regulatory T cells in human peripheral blood. Eur J Immunol 2010; 40:1099-106.
17. + regulatory T cells. Curr Dir Autoimmun 2010; 11:119-34.
18. hi T regulatory cells. Blood 2006; 108:253-61.
19. Kleijwegt FS, Laban S, Duinkerken G, Joosten AM, Zaldumbide A, Nikolic T, Roep BO. Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. J Immunol 2010; 185:1412-8.
20. + T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol 2010; 40:2891-901.
21. Ma HL, Napierata L, Stedman N, Benoit S, Collins M, Nickerson-Nutter C, Young DA. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum 2010; 62:430-40.
22. Mougiakakos D, Johansson CC, Jitschin R, Bottcher M, Kiessling R. Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress. Blood 2011; 117:854-61.
23. Grinberg-Bleyer Y, Saadoun D, Baeyens A et al. Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J Clin Invest 2010; 120:4558-68.
24. + regulatory T cells. J Immunol 2010; 185:174-82.
25. van der Most RG, Currie AJ, Mahendran S, Prosser A, Darabi A, Robinson BW, Nowak AK, Lake RA. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother 2009; 58:1219-28.
26. - regulatory T cells. Proc Natl Acad Sci USA 2002; 99:13031-6.
27. + human thymocytes. J Exp Med 2002; 196:379-87.
28. - regulatory T cells that modulates their suppressive function. J Immunol 2010; 184:3570-81.
29. Minigo G, Woodberry T, Piera KA et al. Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS Pathog 2009; 5:e1000402.
30. + regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum 2004; 50:2775-85.
31. Kryczek I, Liu R, Wang G et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 2009; 69:3995-4000.
32. Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR. Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer 1994; 56:777-82.
33. Pusztai L, Clover LM, Cooper K, Starkey PM, Lewis CE, McGee JO. Expression of tumour necrosis factor alpha and its receptors in carcinoma of the breast. Br J Cancer 1994; 70:289-92.
34. Trentin L, Zambello R, Bulian P et al. Tumour-infiltrating lymphocytes bear the 75kDa tumour necrosis factor receptor. Br J Cancer 1995; 71:240-5.
35. + regulatory T cell function. Science 2008; 322:271-5.
36. + T regulatory cells. J Immunol 2007; 179:154-61.
37. Bilate AM, Lafaille JJ. Can TNF-alpha boost regulatory T cells? J Clin Invest 2010; 120:4190-2.
38. + regulatory T cells by 1, 25-dihydroxyvitamin D3. Blood 2005; 106:3490-7.
39. + regulatory T cells. Eur J Immunol 2011; In press. doi: .
40. Kim HP, Leonard WJ. The basis for TCR-mediated regulation of the IL-2 receptor alpha chain gene: role of widely separated regulatory elements. EMBO J 2002; 21:3051-9.
41. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002; 2:364-71.
42. Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86:242-51.
43. Kollias G, Kontoyiannis D, Douni E, Kassiotis G. The role of TNF/TNFR in organ-specific and systemic autoimmunity: implications for the design of optimized 'anti-TNF' therapies. Curr Dir Autoimmun 2002; 5:30-50.
44. Cope AP. Regulation of autoimmunity by proinflammatory cytokines. Curr Opin Immunol 1998; 10:669-76.
45. Clark J, Vagenas P, Panesar M, Cope AP. What does tumour necrosis factor excess do to the immune system long term? Ann Rheum Dis 2005; 64(Suppl. 4):iv70-6.
46. Kollias G, Kontoyiannis D. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev 2002; 13:315-21.
47. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004; 200:277-85.
48. + T cells in patients with active rheumatoid arthritis is reduced by infliximab. Ann N Y Acad Sci 2005; 1051:506-14.
49. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007; 204:33-9.
50. + T cells that inhibit protective immunity in murine histoplasmosis. J Immunol 2008; 180:1088-97.
51. + T cell suppressor function. Eur J Immunol 2004; 34:366-76.
52. Biton J, Semerano L, Delavallee L, Lemeiter D, Laborie M, Grouard-Vogel G, Boissier MC, Bessis N. Interplay between TNF and regulatory T cells in a TNF-driven murine model of arthritis. J Immunol 2011; 186:3899-910.
53. Lewis M, Tartaglia LA, Lee A, Bennett GL, Rice GC, Wong GH, Chen EY, Goeddel DV. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci USA 1991; 88:2830-4.